Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments

(2022) Julia Moreno-Vicente et al.   Journal for ImmunoTherapy of Cancer

2O Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties

(2021) B. Li et al.   ANNALS OF ONCOLOGY

909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results

(2021) X. Chen et al.   ANNALS OF ONCOLOGY

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).

(2021) Yuqin Song et al.   JOURNAL OF CLINICAL ONCOLOGY

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

(2020) Kurt A. Schalper et al.   NATURE MEDICINE

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

(2020) Kobe C. Yuen et al.   NATURE MEDICINE

The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer

(2020) Rodolfo Bianchini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy

(2020) Hui Wang et al.   Journal for ImmunoTherapy of Cancer

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

(2018) Tong Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment

(2018) Hirotake Tsukamoto et al.   CANCER RESEARCH

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

(2018) Ahmed T. Kurdi et al.   MOLECULAR CANCER THERAPEUTICS

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

(2018) Giuseppe Lo Russo et al.   CLINICAL CANCER RESEARCH

Optimization of high-concentration endostatin formulation: Harmonization of excipients’ contributions on colloidal and conformational stabilities

(2017) Shujing Wang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

(2017) Petros Fessas et al.   SEMINARS IN ONCOLOGY

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

(2017) Shuguang Tan et al.   Nature Communications

Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells

(2017) Masahiro Okada et al.   Cell Reports

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

(2016) Zhenkun Na et al.   CELL RESEARCH

IgG4 Characteristics and Functions in Cancer Immunity

(2016) Silvia Crescioli et al.   CURRENT ALLERGY AND ASTHMA REPORTS

Biological roles of glycans

(2016) Ajit Varki   GLYCOBIOLOGY

Investigating interactions between phospholipase B-Like 2 and antibodies during Protein A chromatography

(2016) Benjamin Tran et al.   JOURNAL OF CHROMATOGRAPHY A

Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles

(2016) Nitin Dixit et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1

(2016) Shoichiro Horita et al.   Scientific Reports

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

(2015) B Homet Moreno et al.   BRITISH JOURNAL OF CANCER

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions

(2015) Michelle Kinder et al.   mAbs

Examination of Thermal Unfolding and Aggregation Profiles of a Series of Developable Therapeutic Monoclonal Antibodies

(2015) Mark L. Brader et al.   MOLECULAR PHARMACEUTICS

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

IgG4 subclass antibodies impair antitumor immunity in melanoma

(2013) Panagiotis Karagiannis et al.   JOURNAL OF CLINICAL INVESTIGATION

Structural Determinants of Unique Properties of Human IgG4-Fc

(2013) Anna M. Davies et al.   JOURNAL OF MOLECULAR BIOLOGY

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

(2013) F. Mimoto et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

(2011) J. Pander et al.   CLINICAL CANCER RESEARCH

Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength

(2011) A. F. Labrijn et al.   JOURNAL OF IMMUNOLOGY

Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells

(2011) Y.-C. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Influence of pH on Heat-Induced Aggregation and Degradation of Therapeutic Monoclonal Antibodies

(2010) Tomoyoshi Ishikawa et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Human IgG4 Binds to IgG4 and Conformationally Altered IgG1 via Fc-Fc Interactions

(2009) T. Rispens et al.   JOURNAL OF IMMUNOLOGY

Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression

(2009) Ivan O. Potapenko et al.   Molecular Oncology